Pacer Advisors Inc. Buys 403,028 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Pacer Advisors Inc. increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 29.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,752,882 shares of the specialty pharmaceutical company's stock after acquiring an additional 403,028 shares during the period. Pacer Advisors Inc. owned about 3.17% of Supernus Pharmaceuticals worth $54,655,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Armistice Capital LLC boosted its holdings in Supernus Pharmaceuticals by 47.6% during the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company's stock valued at $141,026,000 after purchasing an additional 1,700,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Supernus Pharmaceuticals by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company's stock worth $76,690,000 after buying an additional 309,966 shares during the period. Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company's stock valued at $60,246,000 after buying an additional 33,710 shares in the last quarter. Renaissance Technologies LLC grew its position in Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock valued at $45,077,000 after acquiring an additional 351,900 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Supernus Pharmaceuticals by 1.1% during the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company's stock worth $23,163,000 after acquiring an additional 7,833 shares in the last quarter.

Insiders Place Their Bets

In other news, Director Georges Gemayel sold 14,213 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares in the company, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on SUPN shares. Cowen restated a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. Finally, Piper Sandler reiterated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN traded up $0.40 during trading on Friday, reaching $36.22. The company had a trading volume of 208,168 shares, compared to its average volume of 445,763. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37. The business's 50 day moving average price is $33.72 and its 200-day moving average price is $31.10. The stock has a market cap of $2.00 billion, a PE ratio of 33.85 and a beta of 0.86.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.29) EPS. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.